Asian shares, dollar rise after Fed; focus now on BOJ | Reuters
TOKYO Asian stocks rose on Thursday after the U.S. Federal Reserve offered few clues on its monetary policy outlook, while the dollar edged higher as investors awaited the Bank of Japan's policy decision. MSCI's broadest index of Asia-Pacific shares outside Japan .MIAPJ0000PUS added 0.3 percent
TOKYO Asian stocks rose on Thursday after the U.S. Federal Reserve offered few clues on its monetary policy outlook, while the dollar edged higher as investors awaited the Bank of Japan's policy decision.
MSCI's broadest index of Asia-Pacific shares outside Japan .MIAPJ0000PUS added 0.3 percent. Japan's Nikkei .N225 jumped 1.1 percent, while S&P 500 e-mini futures ESc1 edged up 0.1 percent, after Wall Street posted solid gains overnight.
In its statement issued after its meeting on Wednesday, the Fed left interest rates unchanged on Wednesday, but kept the door open to a hike in June while showing little sign it was in a hurry to tighten.
"The committee continues to closely monitor inflation indicators and global economic and financial developments," the Fed said following its two-day meeting.
The BOJ's policy decision, which is often announced around noon in Tokyo, or 0300 GMT, will be a close call.
Policymakers are likely hesitant to take further steps after unveiling their negative interest rate policy in January, though a strong yen and receding inflation expectations could prompt them to ease further.
Data issued early on Thursday showed Japan's core consumer price index fell 0.3 percent from the year-ago period, compared with economists' median estimate for a 0.2 percent gain.
Separate data showed industrial output rose more than expected and labour demand jumped to the highest in two decades, but renewed worries about weak private consumption are likely to temper any optimism about the economy.
"USD/JPY is likely to fall steeply if there is no change in policy," Sean Callow, senior currency strategist at Westpac in Sydney, said in a note to clients. "Most likely there will be at least some tweaks of the existing suite of policies."
The dollar edged up 0.2 percent to 111.61 yen JPY=, moving back towards a three-week high of 111.90 notched on Monday.
The euro was steady at $1.1324 EUR=.
U.S. crude futures CLc1 were down 0.2 percent in early Asian trading at $45.22 a barrel, after hitting their 2016 high of $45.62 following the Fed's decision. Brent LCOc1 also rose to the highest for this year at $47.45, but shed 0.3 percent in Asian trade to $47.04. [O/R]
Earlier in the session, the Reserve Bank of New Zealand kept its benchmark interest rate unchanged at 2.25 percent, but reiterated further easing may be needed given weak inflation.
The decision propelled the New Zealand dollar NZD=D4 up 1.6 percent to $0.6919, after it rocketed as high as $0.6944.
Brazil's central bank also left interest rates unchanged late on Wednesday, leaving its benchmark Selic rate BRCBMP at 14.25 percent for the sixth straight meeting in its fight against high inflation in what could be the current board's last decision ahead of that country's likely change of government.
(Reporting by Lisa Twaronite; Editing by Eric Meijer & Shri Navaratnam)
This story has not been edited by Firstpost staff and is generated by auto-feed.
By Deena Beasley and Julie Steenhuysen (Reuters) -U.S. regulators on Monday approved Biogen Inc's aducanumab as the first treatment to attack a likely cause of Alzheimer's disease despite controversy over whether the clinical evidence proves the drug works. Aducanumab aims to remove sticky deposits of a protein called amyloid beta from the brains of patients in earlier stages of Alzheimer's in order to stave off its ravages, which include memory loss and the inability to care for one's self.
By Arpan Varghese (Reuters) - Gold held on to gains as the dollar slid on Monday, with investors awaiting U.S. inflation data later this week for clarity on when the Federal Reserve might start tapering economic support measures. Spot gold rose 0.3% to $1,895.77 per ounce by 01:42 p.m
By Aftab Ahmed NEW DELHI (Reuters) - India may raise spending on COVID-19 shots by over a quarter this fiscal year to up to 450 billion rupees ($6.18 billion) from its budgeted amount, two government sources told Reuters after the prime minister offered free doses to all adults.